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Escherichia coli O157:H7 is a notorious pathogen often contracted by intake of
contaminated water or food. Infection with this agent is associated with a broad spectrum
of illness ranging from mild diarrhea and hemorrhagic colitis to the potentially fatal
hemolytic uremic syndrome (HUS). Treating E. coli O157:H7 infection with antimicrobial
agents is associated with an increased risk of severe sequelae such as HUS. The
difficulty in treating this bacterium using conventional modalities of antimicrobial agent
administration has sparked an interest in investigating new therapeutic approaches to
this bacterium. These approaches have included the use of probiotic agents and natural
products with variable success rates. In addition, novel modalities and regimen of
antimicrobial agent administration have been assessed in an attempt at decreasing their
association with aggravating infection outcomes.
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GENERAL CHARACTERISTICS OF E. coli O157:H7
The identification of E. coli O157:H7 as the etiologic agent
of an outbreak of gastroenteritis that occurred in 1982 (Riley
et al., 1983) has led to the recognition of a novel class of
E. coli, the Enterohemorrhagic E. coli (EHEC). This group of
pathogenic E. coli includes those that cause a clinical disease
similar to that caused by E. coli O157:H7 and that possess few
other characteristics of this organism, namely producing one
or more phage-encoded Shiga toxins, possessing a hemolysin-
encoding 60MDa plasmid and that cause attaching and effac-
ing (A/E)lesions (Levine, 1987; Nataro and Kaper, 1998).E. coli
O157:H7 produces either or both of two toxins, one neutralized
by antisera to shiga toxin produced by Shigella dysenteriae type 1
and referred to as Shiga toxin 1 (Stx1) while the other, Shiga toxin
2 (Stx2), is not neutralized by these antisera (Strockbine et al.,
1986). Although E. coli O157:H7, like other E. coli ferments lac-
tose, it does not ferment sorbitol within 48 h, unlike 80–95% of
E. coli isolated from human stools (March and Ratnam, 1986).
On the other hand, it does not grow well at 44–45.5◦C, which is
the default incubation temperature for detection of E. coli in food
and water sources (Raghubeer and Matches, 1990).
Disease caused by E. coli O157:H7 has been reported from
more than 30 countries on six continents (Doyle et al., 2001).
In a 20-year surveillance period in the USA, 350 outbreaks were
reported (Rangel et al., 2005). The Center for Disease Control and
Prevention (CDC) estimates that E. coli O157: H7 causes 73,480
illnesses, 2168 hospitalizations and 61 deaths per year in the USA
alone (Mead et al., 1999). E. coliO157:H7 has been found in cattle
of several countries including the USA, Canada, Germany, Spain,
England, and Scotland (Armstrong et al., 1996). Outbreaks have
also occurred in these countries, as well as in Japan (Michino
et al., 1999).
Cattle are considered to be the chief animal reservoir for E. coli
O157:H7, which is a temporary member of their normal gut
micro flora (Caprioli et al., 2005). E. coli O157:H7 has been iso-
lated from many healthy cattle and has not been shown to be a
pathogen in these animals. Cattle seem to lack vascular recep-
tors for shiga-like toxins (Pruimboom-Brees et al., 2000). E. coli
O157:H7 has also been isolated from other animals including deer
(Diaz et al., 2011), sheep (Urdahl et al., 2003), horses (Lengacher
et al., 2010), goats (Mersha et al., 2010), and dogs (Kataoka et al.,
2010).
The first outbreak of E. coli O157:H7 occurred in 1982 and
was traced to contaminated hamburger meat (Riley et al., 1983).
Most outbreaks, particularly those that occurred during the 1980s
were food borne with the main culprits being beef products
particularly undercooked hamburgers in addition to unpasteur-
ized milk (Griffin and Tauxe, 1991). During the past decade,
however, marked changes in the epidemiology of human infec-
tions have taken place and outbreaks traced to vegetable and
fruit sources, in addition to other food sources are on the rise.
Infections traced to white radish sprouts (Michino et al., 1999),
fresh spinach (Brandl, 2008), and lettuce (Hilborn et al., 1999).
Consumption of tomatoes and apple juice has been frequently
involved in outbreaks as well (McDowell and Sheridan, 2001). In
addition, waterborne outbreaks have occurred (Swerdlow et al.,
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1992; Olsen et al., 2002; Bopp et al., 2003). E. coli O157:H7
appears to be capable of survival for prolonged times in water
particularly at lower temperatures (Wang and Doyle, 1998). This
microorganism was demonstrated to survive for more than eight
months in a farm water gutter, and the surviving organisms were
able to colonize cattle (Kudva et al., 1998). Swimming in con-
taminated water has also resulted in outbreaks (Keene et al.,
1994; Friedman et al., 1999; Paunio et al., 1999). Person-to-
person transmission has also been reported in day care centers
and nursing homes as well (Panaro et al., 1990; Reida et al.,
1994).
The rather easy spreading of E. coli O157:H7 from one per-
son to another indicates that the infectious dose is rather low.
Moreover, transmission by water, which would tend to dilute the
organisms, substantiates this suggestion. The estimated infectious
dose from outbreak data is 10–100 CFU (Griffin et al., 1994).
VIRULENCE FACTORS OF E. coli O157:H7
The ability to produce one or more shiga toxins is a hallmark
E. coli O157:H7 infection. However, toxin production is not
sufficient to cause disease. Two other factors are indicted in con-
tributing to the virulence of E. coliO157:H7. The first of these two
factors is harboring a 60 MDa virulence plasmid (pO157), which
encodes a hemolysin (Schmidt et al., 1996; Mead and Griffin,
1998). The other factor is the locus of enterocyte effacement
(LEE) (Kresse et al., 1998; Ogierman et al., 2000).
THE LOCUS OF ENTEROCYTE EFFACEMENT (LEE)
The LEE contains all the genes necessary for inducing the A/E
lesions typical of E. coli O157: H7 infection (Louie et al., 1993;
Vallance and Finlay, 2000). As E. coli O157:H7 attaches to the gut
mucosa and interacts with it, histopathological changes are pro-
duced in the epithelium. These changes are collectively known
as A/E lesions (Kresse et al., 2000). These lesions are character-
ized by effacement of the epithelial brush border microvilli and
the formation of actin-rich pedestals within the host cell under-
neath the attached bacterial cells. The presumed functions of
these pedestals are prevention of dislodgement of the bacterium
during the host diarrheal response and inhibition of bacterial
phagocytosis (DeVinney et al., 1999).
PO157
All isolates of E. coliO157:H7 harbor the 60MDa pO157 plasmid.
This plasmid contains the hly operon encoding an enterohe-
molysin (Schmidt et al., 1996). This hemolysin, with the aid of
specialized transport systems, may allow the bacterium to utilize
the blood released into the intestine as a source of iron (Mead and
Griffin, 1998).
SHIGA TOXINS
The Shiga toxin family comprises three members. Shiga toxin,
produced by Shigella dysenteriae type 1, is the prototype Shiga
toxin. On the other hand, Stx1 and Stx2 are produced by the
EHEC. Several variants of Stx2 have been identified as well and
these include Stx2c, Stx2d, Stx2e, Stx2f, and Stx2g. These share
84–99% of the amino-acid sequence of Stx2 but differ in some
of its biological characteristics (Ito et al., 1990; Melton-Celsa and
O’Brien, 1998; Schmidt et al., 2000; Melton-Celsa et al., 2002;
Zheng et al., 2008). Three functional properties characterize the
Shiga toxin family. These toxins are cytotoxic to HeLa and Vero
cells. They lead to fluid accumulation in ligated rabbit illeal loops;
therefore, they are “enterotoxic” and they are capable of inducing
paralysis of the hind-legs and death in rabbit and mouse models
(Jackson, 1990).
The binding moiety of these toxins, which aids them in
binding to human and animal cells, consists of five B sub-
units. These subunits are non-covalently associated with an A
subunit, which in turn consists of an A1 and an A2 subunit
(Sandvig and Van Deurs, 1996). Shiga toxin and Stx1 differ
only by a single amino acid in the B subunit (Calderwood
et al., 1987; Hofmann, 1993). Thus, they are essentially identi-
cal; moreover, Stx1 is neutralized by antiserum to Shiga toxin
(O’Brien and Holmes, 1987; Qadri and Kayali, 1998). Stx2 is
antigenically distinct and unrelated. It is approximately 55%
homologous to Shiga toxin/Stx1 (Jackson, 1990) and is not
neutralized by antiserum to Shiga toxin (Qadri and Kayali,
1998).
The cellular receptors for the Shiga toxins are the neutral gly-
colipids globotriosylceramide (Gb3) and globotetraosylceramide
(Gb4) (Betz et al., 2011). Various cell types are sensitive to
Shiga toxins. These include enterocytes, renal, aortic, and brain
endothelial cells, mesangial cells, renal tubular and lung epithe-
lial cells, cells of the monocytic lineage, polymorphonuclear cells,
in addition to platelets and erythrocytes among other cell types
(Meyers and Kaplan, 2000).
After the toxin binds its receptor on the cell membrane, a short
incubation leads to aggregation of toxin-receptor complexes in
clathrin-coated pits. Next, the A fragment is endocytosed. The
toxin is transported through endosomes to the Trans Golgi net-
work (TGN). In the TGN, the toxin is cleaved by the enzyme
furin into the A1 and A2 subunits. From the TGN, the toxin
is transported to the endoplasmic reticulum where transloca-
tion into the cytosol takes place. If toxin was not cleaved by
furin, then the cytosolic enzyme caplain may cleave the molecule
(Hofmann, 1993; Sandvig and Van Deurs, 1996). The A1 subunit
is a 28S rRNAN-glycosidase (Jackson, 1990). The toxin cleaves an
adenine residue from a specific nucleotide of the 28S rRNA com-
ponent of the 60S ribosomal subunit. This blocks tRNA binding
to the 60S ribosomal subunit thus preventing peptide elonga-
tion and disrupting protein synthesis. This leads to cell death
(Hofmann, 1993).
Shiga toxins induce an increase in chemokine synthesis from
intestinal epithelial cells. This augments host mucosal inflam-
matory responses with release of interleukins, such as IL-8 and
IL-1, in addition to Tumor Necrosis Factor (TNF). Activation of
human endothelium by TNF or IL-1 leads to an increase in toxin
receptor synthesis and hence increased sensitivity of the cell lead-
ing to increased cell death after exposure to the toxins (Meyers
and Kaplan, 2000).
E. coliO157:H7 strains may produce either Stx1, Stx2, or both;
however, most strains produce Stx2 (Mead and Griffin, 1998).
Stx1 remains mostly cell-associated and stored in the periplasmic
space while Stx2 is released from bacterial cells. Therefore, Stx1
is typically predominantly detected in cell lysates, while Stx2 is
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found in higher titers in culture supernatants (Strockbine et al.,
1986; Yoh et al., 1997; Sato et al., 2003; Shimizu et al., 2009).
OTHER VIRULENCE FACTORS
While the LEE, pO157 and Shiga toxin production are defining
virulence factors of E. coliO157:H7, other factors contribute to its
pathogenicity. Some strains harbors EspP, which belongs to the
family of serine protease autotransporters of Enterobacteriaceae
(SPATE). This protease cleaves pepsin A and human coagulation
factor V, which probably contributes to increased hemorrhage
into the intestinal tract (Brunder et al., 1997). Moreover, EspP
cleaves multiple complement system components hence protect-
ing the bacterium from immune system-mediated elimination
(Orth et al., 2010). On the other hand, in addition to LEE
members such as intimin and Tir, bacterial attachment to host
intestinal cells is also mediated by a type IV pilus referred to as the
hemorrhagic coli pilus (HCP) (Xicohtencatl-Cortes et al., 2007).
Multiple fimbriae and fimbrial gene clusters have also been impli-
cated in contributing to adherence of this organism to host cells
(Low et al., 2006).
CLINICAL ILLNESSES ASSOCIATEDWITH E. coli O157:H7
INFECTIONS
Infection with E. coliO157:H7 can be asymptomatic or may man-
ifest as non-bloody diarrhea, hemorrhagic colitis, the hemolytic
uremic syndrome (HUS), thrombocytopenia purpura and death
(Griffin et al., 1988).
HEMORRHAGIC COLITIS
Unless infection with E. coli O157:H7 is asymptomatic, following
an incubation period of 3–4 days (Nauschuetz, 1998), the illness
starts with severe abdominal cramps accompanied by a non-
bloody diarrhea. In most patients the watery diarrhea becomes
grossly bloody after two or three days (Boyce et al., 1995). Fever
may be totally absent ormay be of the low-grade type and its pres-
ence is more common in patients with severe illness (Griffin et al.,
1988; Slutsker et al., 1997).
The duration of E. coli O157:H7 shedding seems to be age-
dependent. Children under five years of age carry the organism
after the resolution of symptoms longer than older children and
adults (Pai et al., 1988). Intermittent shedding has also been
reported (Belongia et al., 1993).
THE HEMOLYTIC UREMIC SYNDROME
Gastrointestinal symptoms due to infection with E. coli O157:H7
usually resolve within a week. Patients then mostly recover with
no major sequelae. Nevertheless, 5–10% of patients under the age
of 10 years develop the HUS approximately one week after onset
of hemorrhagic colitis. The release of Shiga toxins is believed to
play a central role in the development of HUS (Karmali et al.,
1983). HUS most commonly occurs in children between 1 and
5 years of age but it can also occur in other groups particularly
hospitalized patients over the age of 60 years. HUS displays a
classical triad of microangiopathic hemolytic anemia (with frag-
mented RBCs on blood film), thrombocytopenia and renal failure
(Gasser et al., 1955; Gianantonio et al., 1964). The patient’s hema-
tocrit may decline by 10%. Oligouria and hypertension (with
elevated serum potassium, blood urea nitrogen, and uric acid
levels) may occur as well. A condition known as thrombotic
thrombocytopenia purpura (TTP) strikes mostly the adult pop-
ulation and is rarer than HUS. In TTP less marked renal damage
is noted and fewer cases have a diarrheal prodrome. Both HUS
and TTP can present with neurological abnormalities includ-
ing seizures, coma and hemiparesis. These two conditions need
not always be differentiated and may be referred to as HUS/TTP
(Nauschuetz, 1998).
HUS and TTP are non-consumptive coagulopathies i.e., char-
acterized by the consumption of platelets but not of clotting
factors. They are regarded as variants of a single syndrome (Van
Gorp et al., 1999). While fever and central nervous system (CNS)
involvement are more frequent in TTP, renal dysfunction is less,
and mortality and recurrences are greater. Although TTP can be
initiated by E. coli O157:H7 infection, a diarrheal prodrome is
uncommon (Siegler, 1995).
Classical postdiarrheal HUS always involves the colon and the
kidney; however, other organ systems may be affected. The brain
is most commonly affected with an evidence of CNS dysfunc-
tion in nearly one-third of HUS cases. Generalized seizures are
common and occur in <20% of children affected. CNS injury
symptoms range from disorders of posture, movement, and mus-
cle tone to coma. Transient hepatocellular damage occurs in 40%
of cases. The pancreas may be involved leading to diabetes mel-
litus, pancreatitis, and rarely, exocrine dysfunction. Other organs
such as the heart, the lung and the skin are involved in rare cases
(Siegler, 1995).
After the onset of the acute phase of HUS, characterized by
the already mentioned triad of hemolytic anemia, thrombocy-
topenia, and acute renal injury, the patient’s clinical disease may
follow one of several patterns. More than 95% of cases recover
from the acute phase of the disease. Thus, the mortality rate is
5% (McLigeyo, 1999). Grave sequelae, such as end-stage renal
disease or permanent neurologic damage, occur in about 5%
of subjects who survive the acute phase of HUS (Boyce et al.,
1995).
Although an E. coli O157:H7 infection may result in HUS and
TTP, numerous other causes may result in these diseases.
PATHOGENESIS OF E. coli O157:H7 INFECTIONS
The infectious process of E. coli O157:H7 (Figure 1) is initiated
by the ingestion a relatively small inoculum of 10–100 CFUs. Only
a few organisms are needed to allow enteric colonization (Mead
and Griffin, 1998). The process by which these bacteria become
attached to the mucosa of the distal ileum and the colon is com-
plex and likely starts by bacterial fimbrial attachment followed by
translocation of the bacterial Tir protein to the host cell mem-
brane. Tir serves as the receptor for intimin, which is a bacterial
outer membrane protein that plays a major role in attachment
and production of A/E lesions characterized by effacement of
microvilli (DeVinney et al., 1999).
Owing to this bacterium’s tremendous ability to produce the
potent cytotoxic Shiga toxins, invasion of the host cells is not
necessary for the progression to hemorrhagic colitis. Although
the toxins are probably also not necessary for triggering the diar-
rhea, they most likely cause the intestinal lesions, characterized by
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FIGURE 1 | The pathobiologic process of E. coli O157:H7. The complex
process by which E. coli O157:H7 attaches to the intestinal mucosa starts
by bacterial fimbrial attachment followed by translocation of the bacterial Tir
protein into the host cell membrane. Tir serves as the receptor for the
bacterial outer membrane attachment protein intimin. One or more types of
Shiga toxins are released which then bind to their cellular receptors, the
neutral glycolipids Gb3 and Gb4. Internalization and cellular activation of
these toxins blocks ribosomal peptide elongation hence disrupting protein
synthesis leading to cell death. Intestinal damage permits Shiga toxins and
other bacterial factors to gain entrance to the circulation. These may reach
multiple host tissues including the kidneys where damage to the
microvasculature results in the potentially lethal hemolytic uremic
syndrome. Treatment of this disease remains largely supportive with no
widely accepted antibacterial or toxin-targeted regimen. Antibacterial
agents are believed to result in bacterial lysis and release of stored toxins.
One potential treatment method may rely on inhibition of toxin expression
prior to administration of a bactericidal agent.
hemorrhage and ulcerations, via damaging the microvasculature
of the intestinal wall (Tesh and O’Brien, 1992).
Once the gut-blood barrier has been compromised by
intestinal damage, Shiga toxins, and other bacterial products like
lipopolysaccharide (LPS) gain entrance to the circulation. LPS
can by itself, independent of Shiga toxins, damage endothelial
cells, increase TNF levels, activate platelets and induce the blood
coagulation cascade. It can also increase levels of interleukins
such as IL-8, which is a potent activator of white blood cells
(WBCs). WBCs participate in the pathogenic process by elaborat-
ing tissue-damaging enzymes such as elastase. Shiga toxins induce
an increase in chemokine synthesis from intestinal epithelial cells
probably augmenting host mucosal inflammatory responses with
release of IL-8, TNF, and IL-1. As mentioned above, activation
of human endothelium by TNF or IL-1 leads to an increase
in expression of the Shiga toxin cellular receptors. This leads to an
increased cell death after exposure to the toxins. Since the toxin
receptors are widely distributed on various types of cells, thus
many host tissues are affected (Meyers and Kaplan, 2000).
CURRENT AND NOVEL TREATMENT APPROACHES
Treatment of infection with EHEC strains, including E. coli
O157:H7, is mainly based on supportive therapy, particularly
rehydration. The use of antimotility agents, which inhibit peri-
stalsis and delay clearance of the organism, poses a risk factor for
progression to HUS (Cimolai et al., 1994; Bell et al., 1997). The
use of antimicrobial agents in the treatment of E. coli O157:H7
infection is not recommended but remains a debatable issue
(Safdar et al., 2002). This is based on studies that have shown
it to be a risk factor for the development of HUS (Wong et al.,
2000; Smith et al., 2012). Additionally, the use of trimethoprim,
the quinolones, or furazolidone enhances the production of Shiga
toxins from E. coli O157:H7 in vitro presumably due to lysis of
bacterial cells and the release of stored toxins (Kimmitt et al.,
2000). This enhanced release of toxins may alternatively be due
to induction of Stx-producing prophages harbored by the bac-
terium. These prophages would be activated by the SOS response,
a damage response triggered in these bacteria mostly due to
genomic insult which may be exerted by antimicrobial treatment
(Kimmitt et al., 2000).
In light of the difficulties in treating this agent, alternate
treatment approaches were investigated by multiple groups.
Antibodies to Stx2 were shown to enhance the survival of infected
gnotobiotic piglets (Donohue-Rolfe et al., 1999). These antibod-
ies were also demonstrated to be well tolerated in humans and
thus may be useful for preventing HUS in pediatric subjects
(Lopez et al., 2010). On the other hand, carbosilane dendrimers
were shown to specifically bind to Shiga toxins with high affinity
and to inhibit cellular entry of the toxin. Intravenous administra-
tion of these carbosilane dendrimers decreased the brain damage
and prevented the lethal effect of the toxins in infected mice
(Nishikawa et al., 2002).
The use of natural products for the treatment and prevention
of E. coli O157:H7 has been assessed by multiple groups. Studies
in infant rabbits show that the administration of Lactobacillus
casei, commonly known for its probiotic efficiency, had a pro-
tective effect against the toxins of E. coli O157:H7 (Ogawa
et al., 2001). Multiple other probiotic agents have been shown
to be effective in curbing the growth or the pathogenic effect of
this organism (Shu and Gill, 2001, 2002; Asahara et al., 2004;
Takahashi et al., 2004; Gagnon et al., 2006; Kim et al., 2009;
Etienne-Mesmin et al., 2011; Tahamtan et al., 2011). Certain
herbs such as Chinese cinnamon, Spanish oregano and other
essential oils have been shown to have mechanisms of action
against the cell membrane and cell wall of E. coli O157:H7
(Oussalah et al., 2006). Green tea components (Lee et al., 2009)
in addition to cranberry constituents (Lacombe et al., 2010) have
also been shown to have an effect against this bacterium. In an
attempt at implementing antimicrobial agents in the treatment
of an E. coli O157:H7-infected animal model, azithromycin was
shown to enhance the survival of infected piglets (Zhang et al.,
2009). The majority of the studies mentioned herein have limited
their testing to in vitro assays or employed animals that were gno-
tobiotic or treated with antimicrobial agents to limit the growth
of their normal flora prior to infection with E. coli O157:H7.
Consequently, the response to the tested agents in a host with a
normal range of flora may be different.
Our group examined whether employing an agent that would
inhibit toxin expression prior to treatment with a bactericidal
antibiotic may be effective in treating such an infection. We
assessed the effects of rifampicin, an RNA polymerase inhibitor,
and gentamicin, a ribosome inhibitor, on the expression of the
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Stx1 and Stx2 encoding genes, stx1 and stx2 (Kanbar et al., 2003;
Matar and Rahal, 2003; Rahal et al., 2011a,b). After incuba-
tion with antimicrobial agents, levels of stx1 gene transcripts
notably decreased by more than 99% in a sample treated with
the minimum inhibitory concentration (MIC) of rifampicin, in
that treated with theMIC of rifampicin followed by theminimum
bactericidal concentration (MBC) of rifampicin and in the sample
treated with the MIC of rifampicin followed by the MBC of gen-
tamicin. The sample treated with the MBC of gentamicin alone
showed a 51.37% decrease, which was the least noted toxin gene
expression inhibition. A 77% decrease in stx2 transcript detection
was seen in the sample treated with the MBC of gentamcin alone.
Samples treated with the MIC of rifmapicin, or with the MIC of
rifampicin followed by the MBC of rifampicin, or with the MIC
of rifampicin followed by the MBC of gentamicin showed com-
plete inhibition of stx2 transcript detection. Detection of toxin
release from these bacteria using reverse passive latex agglutina-
tion (RPLA) yielded results that were mostly concurrent with
the decrease in RNA synthesis except for samples treated with
the MBC of gentamicin alone. Gentamicin seemed to trigger an
enhanced release of toxins from treated cultures.
To assess the utility of an antimicrobial regimen for the
treatment of an animal model of infection, multiple groups of
BALB/c mice received 3× LD50 of an E. coli O157:H7 strain via
intraperitoneal injection. These were then treated with various
rifampicin/gentamicin regimen and were monitored for survival.
None of the mice infected and left untreated and none of the mice
infected but treated with the in vivo MBC equivalent dose of gen-
tamicin survived. On the other hand, the highest survival rate was
obtained with the group treated with the in vivo MIC equivalent
dose of rifampicin followed by the in vivo MBC equivalent dose
of gentamicin (50% survival rate). In comparison, 25% of the
mice infected and treated with the in vivo MIC equivalent dose
of rifampicin survived while mice treated post-infection with the
in vivo MIC equivalent dose of rifampicin followed by the in vivo
MBC equivalent dose of rifampicin showed a 12.5% survival rate.
Therefore, preliminary data support that antimicrobial agents
may be used for the treatment of an E. coli O157:H7 infection.
One promising treatment modality, as evidenced by our in vivo
data, may be to implement an expression inhibitory dose of an
agent that would limit toxin production prior to using a bacte-
ricidal dose of an antimicrobial. Such a treatment modality may
also be of use in treating other Shiga toxin producing organisms
including emerging agents such as Escherichia coliO104:H4; how-
ever, potential implementation of such a treatment remains to be
assessed.
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